Compare EXPD & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPD | BIIB |
|---|---|---|
| Founded | 1979 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 24.2B |
| IPO Year | N/A | 1991 |
| Metric | EXPD | BIIB |
|---|---|---|
| Price | $151.42 | $181.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 23 |
| Target Price | $129.22 | ★ $176.48 |
| AVG Volume (30 Days) | 1.5M | ★ 1.9M |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | ★ 20.10 | N/A |
| EPS | 6.15 | ★ 10.97 |
| Revenue | ★ $11,167,760,000.00 | $10,065,900,000.00 |
| Revenue This Year | $3.06 | $3.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.64 | ★ $16.52 |
| Revenue Growth | ★ 12.54 | 4.77 |
| 52 Week Low | $100.47 | $110.04 |
| 52 Week High | $151.67 | $185.17 |
| Indicator | EXPD | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 75.95 | 72.92 |
| Support Level | $144.93 | $174.53 |
| Resistance Level | $147.87 | $182.94 |
| Average True Range (ATR) | 2.89 | 5.22 |
| MACD | 0.18 | 0.25 |
| Stochastic Oscillator | 98.14 | 83.54 |
Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. Expeditors derives around 35% of consolidated gross revenue from airfreight, 30% from ocean freight, and 36% from customs brokerage and other services.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).